Analisis Keuangan Saham APS - Aptose Biosciences Inc. (TSX) Stock

Aptose Biosciences Inc.
CA ˙ TSX ˙ CA03835T3091
CA$ 1.65 ↑0.01 (0.61%)
2025-09-05
BAHAGING PRESYO
Gambaran Umum
Aptose Biosciences Inc., based in Canada, operates within the biotechnology sector, focusing primarily on the development of novel therapies that target the underlying mechanisms of cancer. This clinical-stage company concentrates on developing personalized oncology drugs that halt aberrant cell growth and proliferation essential to hematologic cancers and solid tumors. Key projects include HM43239, an oral myeloid kinase inhibitor currently in clinical development for acute myeloid leukemia (AML), and APTO-253, which is the company's leading candidate targeting the c-Myc oncogene in hematologic cancers and solid tumors. These projects reflect Aptose Biosciences' strategic focus on addressing significant unmet medical needs in the oncology field.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai operating income untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah -21.53 MM.
  • Nilai net income untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah -21.12 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 -21.53 -21.12
2025-03-31 -21.96 -21.33
2024-12-31 -26.26 -25.43
2024-09-30 -36.20 -35.80
2024-06-30 -40.91 -40.29
2024-03-31 -48.02 -47.17
2023-12-31 -52.36 -51.21
2023-09-30 -50.63 -49.25
2023-06-30 -48.98 -47.58
2023-03-31 -45.20 -44.02
2022-12-31 -42.60 -41.82
2022-09-30 -56.55 -56.15
2022-06-30 -57.88 -57.70
2022-03-31 -60.70 -60.61
2021-12-31 -65.45 -65.35
2021-09-30 -55.86 -55.74
2021-06-30 -57.79 -57.66
2021-03-31 -60.19 -59.94
2020-12-31 -55.77 -55.24
2020-09-30 -48.89 -48.23
Laporan Laba Rugi: EPS
  • earnings per share basic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -13.04.
  • laba per saham yang terdilusi untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -13.04.
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30 -13.04 -13.04
2025-03-31 -19.03 -19.03
2024-12-31 -36.38
2024-09-30 -76.48 -76.48
2024-06-30 -108.74 -108.74
2024-03-31 -166.58 -166.58
2023-12-31 -227.43
2023-09-30 -233.36 -233.49
2023-06-30 -230.76 -230.76
2023-03-31 -214.49 -216.51
2022-12-31 -203.98
2022-09-30 -275.90 -274.79
2022-06-30 -286.14 -286.31
2022-03-31 -303.30 -299.63
2021-12-31 -330.12 -328.50
2021-09-30 -282.09 -281.46
2021-06-30 -294.28 -292.47
2021-03-31 -317.32 -317.32
2020-12-31 -303.74
2020-09-30 -292.20 -292.20
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah -27.17 MM.
  • Nilai cash from investing activities untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah 0.00 MM.
  • Nilai kas dari aktivitas pendanaan untuk Aptose Biosciences Inc. per 2025 Jun 30 adalah 20.14 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -27.17 0.00 20.14
2025-03-31 -27.01 2.01 22.40
2024-12-31 -35.98 0.02 33.41
2024-09-30 -37.18 1.96 27.46
2024-06-30 -37.34 14.91 22.36
2024-03-31 -45.05 10.93 18.71
2023-12-31 -44.59 9.96 6.91
2023-09-30 -43.98 25.59 6.11
2023-06-30 -40.42 7.56 1.23
2023-03-31 -33.98 19.60 0.15
2022-12-31 -32.32 30.07 0.12
2022-09-30 -39.72 -7.52 0.13
2022-06-30 -40.80 -2.62 0.11
2022-03-31 -42.57 -7.69 0.17
2021-12-31 -43.30 -35.21 0.23
2021-09-30 -37.61 12.76 0.20
2021-06-30 -37.84 8.56 58.48
2021-03-31 -36.16 5.04 58.45
2020-12-31 -33.89 12.63 58.81
2020-09-30 -29.77 -23.61 132.41
Metrik Penilaian: PE, PriceToBook, PriceToTBV
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Efektivitas Manajemen
  • roa untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -1.95.
  • roic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -12.17.
  • croic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -1.48.
  • ocroic untuk Aptose Biosciences Inc. pada 2025 Jun 30 adalah -15.41.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 -1.95 -12.17 -1.48 -15.41
2025-03-31 -1.99 -185.62 -16.02 -4.89 -23.43
2024-12-31 -2.76 -4.19 -0.91 -4.35
2024-09-30 -1.93 -4.60
2024-06-30 -1.20 -1.81 -44.67 -14.60 -42.66
2024-03-31 -1.00 -1.09 -5.82 -3.15 -5.07
2023-12-31 -0.86 -1.05 -5.54 -1.38 -4.95
2023-09-30 -0.73 -0.86 -3.17 -2.11 -2.70
2023-06-30 -0.68 -0.79 -3.17 -2.11 -2.70
2023-03-31 -0.61 -0.67 -1.62 -0.52 -1.25
2022-12-31 -0.58 -0.57 -1.19 -1.00 -0.84
2022-09-30 -0.58 -0.57 -1.19 -1.00 -0.84
2022-06-30 -0.54 -0.59 -1.03 -0.77 -0.73
2022-03-31 -0.53 -0.55 -0.92 -0.76 -0.65
2021-12-31 -0.52 -0.55 -0.87 -1.05 -0.58
2021-09-30 -0.41 -0.43 -0.56 -0.25 -0.38
2021-06-30 -0.68 -0.73 -0.58 0.30 -0.38
2021-03-31 -0.65 -0.69 -0.54 0.25 -0.33
2020-12-31 -0.55 -0.59 -0.46 0.31 -0.28
2020-09-30 -1.49 -1.76 -0.37 0.61 -0.23
Gross Margins
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)882361
Other Listings
DE:LTI0
GB:0UI8
US:APTOF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista